

Preparation of alginate beads for floating drug delivery system: effects of CO₂ gas-forming agents

B.Y. Choi^a, H.J. Park^{a,*}, S.J. Hwang^b, J.B. Park^c

^a Graduate School of Biotechnology, Korea University, Seoul 136-701, South Korea

^b College of Pharmacy, Chungnam National University, Taejon 305-764, South Korea

^c Sama Pharm., Co., Ltd., Uiwang, Kyonggi 437-821, South Korea

Received 13 October 2001; received in revised form 10 January 2002; accepted 4 February 2002

Abstract

Floating beads were prepared from a sodium alginate solution containing CaCO₃ or NaHCO₃ as gas-forming agents. The solution was dropped to 1% CaCl₂ solution containing 10% acetic acid for CO₂ gas and gel formation. The effects of gas-forming agents on bead size and floating properties were investigated. As gas-forming agents increased, the size and floating properties increased. Bead porosity and volume average pore size, as well as the surface and cross-sectional morphology of the beads were examined with Mercury porosimetry and Scanning Electron Microscopy. NaHCO₃ significantly increased porosity and pore diameter than CaCO₃. Incorporation of CaCO₃ into alginate solution resulted in smoother beads than those produced with NaHCO₃. Gel strength analysis indicated that bead strength decreased with increasing gas-forming agent from 9 to 4 N. Beads incorporating CaCO₃ exhibited significantly increased gel strength over control and NaHCO₃-containing samples. Release characteristics of riboflavin as a model drug were studied in vitro. Release rate of riboflavin increased proportionally with addition of NaHCO₃. However, increasing weight ratios of CaCO₃ did not appreciably accelerate drug release. The results of these studies indicate that CaCO₃ is superior to NaHCO₃ as a gas forming agent in alginate bead preparations. The enhanced buoyancy and sustained release properties of CaCO₃-containing beads make them an excellent candidate for floating drug dosage systems (FDDS). © 2002 Published by Elsevier Science B.V.

Keywords: Alginate bead; Floating bead; Floating drug dosage system (FDDS); Gas-forming agent; NaHCO₃; CaCO₃

1. Introduction

Oral sustained drug delivery system is complicated by limited gastric residence times (GRTs). Rapid GI transit can prevent complete drug re-

lease in the absorption zone and reduce the efficacy of the administered dose since the majority of drugs are absorbed in stomach or the upper part of small intestine (Rouge et al., 1996).

To overcome these limitations, several controlled oral drug delivery systems with prolonged gastric residence times have been reported recently such as: floating drug dosage systems (FDDS) (Baumgartner et al., 2000; Bulgarelli et al.,

* Corresponding author. Tel.: +82-2-3290-3450; fax: +82-2-927-9028.

E-mail address: hjpark@korea.ac.kr (H.J. Park).

2000; Deshpande et al., 1997; Singh and Kim, 2000; Timmermans and Moes, 1994), swelling or expanding systems (Chen and Park, 2000), mucoadhesive systems (Akiyama et al., 1998; Chickering et al., 1997), modified-shape systems (Kedzierewicz et al., 1999), high-density systems (Rouge et al., 1998), and other delayed gastric emptying devices. Among these systems, FDDS have been most commonly used.

FDDS have a lower density than gastric fluids and thus remain buoyant in the stomach without affecting the gastric emptying rate for a prolonged period of time. While the system is floating in the gastric content, the drug is released slowly from the system at a desired rate.

Materials used for FDDS include carbon dioxide gas-forming agents (carbonate or bicarbonate compounds) (Baumgartner et al., 2000; Chen and Park, 2000, Johnson et al., 1997), highly swellable hydrocolloids and light mineral oils (Desai and Bolton, 1993; Murata et al., 2000). Multiple unit systems (Iannuccelli et al., 1998; Ichikawa et al., 1991; Rouge et al., 1998) and hollow systems prepared by solvent evaporation methods (El-Kamel et al., 2001; Kawashima et al., 1992; Thanoo et al., 1993) have also been developed.

In this paper the floating drug delivery system employs calcium carbonate (CaCO_3) or sodium bicarbonate (NaHCO_3) as a gas-forming agent dispersed in an alginate matrix. Alginate is a polysaccharide which contains varying amounts of 1,4'-linked β -D-mannuronic acid, α -L-guluronic acid residues. As biocompatible and biodegradable biopolymer, it forms a bio-adhesive and stable gel with divalent cations such as Ca^{2+} , Sr^{2+} , and Ba^{2+} (Grant et al., 1973; Smidsrod and Haug, 1965). These properties have enabled widespread use for sustained release of drugs (Badwan et al., 1985; Gray and Dowsett, 1988). They can also function as carriers of *Bifidobacteria* (Sultana et al., 2000) since alginate beads are stable in acidic media and easily depredated in alkaline media. Floating alginate beads are particularly effective for site-specific controlled release of antibacterial agents effective against harmful stomach bacteria such

as *H. pylori* (Katayama et al., 1999; Whitehead et al., 2000).

During formation of the floating drug beads, carbonate salts are reacted with acetic acid to produce carbon dioxide. The evolving gas permeates through the alginate leaving gas bubbles or pores. NaHCO_3 has frequently been employed as a gas-forming agent for FDDS (Baumgartner et al., 2000; Chen and Park, 2000; Mandel et al., 2000; Park et al., 2001; Zaniboni et al., 1995). However, its effect on physical properties such as size, mechanical strength and dissolution rate of FDDS has not been reported. There are few records of research on CaCO_3 or other gas-forming agents. Until now, CaCO_3 has only been used as a gelling agent to make alginate gel (Catherine and Peter, 2001; Poncetlet et al., 1999).

The aim of this experiment is to prepare a floating controlled drug delivery system using gas-forming agents. The effects of CO_2 gas-formation on the physical properties, morphology, and release rate of alginate beads are examined. The comparative efficacy of CaCO_3 and NaHCO_3 as gas forming agents for FDDS is also evaluated. Riboflavin was chosen as a model drug for this study because its release must be specially targeted to the stomach and upper intestine (Akiyama et al., 1998; Deshpande et al., 1997; Zaniboni et al., 1995). The inefficiency of oral sustained-release riboflavin formulations has presented an ideal application for FDDS.

2. Materials and methods

2.1. Materials

Sodium alginate (low viscosity grade; 250 cp in 2% solution at 25 °C and hydroxypropylmethylcellulose (HPMC) were purchased from Sigma (St Louis, MO, USA). Riboflavin was obtained from Junsei Chemical (Tokyo, Japan). Calcium carbonate and sodium bicarbonate were purchased from Yakuri Pure Chemical (Osaka, Japan) and Duksan Pure Chemical (Kyungki,

Korea), respectively. All other chemicals were of analytical grade.




2.2. Preparation of floating alginate beads

A solution was prepared by dissolving 0.09 g riboflavin in 5 ml distilled water. The solution was dispersed in 30 ml alginate solution (3%, w/v) containing HPMC (alginate:HPMC = 9:1, w/w). Then, gas-forming agent such as NaHCO_3 or CaCO_3 was added to the solution with levels from 0:1 to 1:1 (gas-forming agent/alginate, w/w). The mixture was then degassed under vacuum. The resulting solution was dropped through a 26G syringe needle into 1% (w/v) CaCl_2 solution containing 10% (v/v) acetic acid. The solution containing suspend beads was stirred with a magnetic stir bar for 10 min to improve the mechanical strength of the beads and allowed to complete the reaction to produce gas. Since the carbonate salts are insoluble at neutral pH, the divalent ions were only released in the presence of acid (Scheme 1), thereby preventing premature gelation. The fully formed beads were collected, washed with ethanol and distilled water, and subsequently freeze-dried.

Mixture (alginate/HPMC, gas-forming agent, riboflavin)



Dropping into CaCl_2 /acetic acid solution



Separation



Freeze dry

Scheme 1.

2.3. Bead characterization

2.3.1. Size analysis

The average diameter of ten wet and dry beads was determined using a caliper (Mitutoyo, Japan) in triplicate.

2.3.2. Bead porosity and mean pore diameter

The bead porosity was assessed using mercury porosimetry (AutoPore IV 9500 V1.03, Micromeritics, GA, USA) ($n = 2$). The pressure was varied from 0 to 50 psi. A 10 s equilibration time was set for each intermediate data point. At each equilibrium point, mercury intrusion data were recorded and plotted against pressure. Standard values for the contact and surface tension of mercury were used.

2.3.3. Morphological analysis

Surface and cross-sectional morphologies of beads were examined with a Scanning Electron Microscope (SEM) (JSM-5310LV Scanning Microscope, Tokyo, Japan). Beads were mounted on metal grids using double-sided tape and gold coated under vacuum.

2.3.4. Mechanical strength study

To precisely measure mechanical strength of the alginate gel beads, large beads were prepared by replacing 26G syringe with 1 ml pipette aid (Gilson, Germany) as the method described above. However, the samples were not freeze-dried. Compression testing was performed with an Instron 4460 (Instron Corporation, Canton, MA). Ten beads of identical size were selected. Crosshead speed and probe diameter were set at 1 mm/min and 3.5 mm, respectively.

2.4. In vitro evaluation

2.4.1. Floating properties

Floating properties of wet and dry beads were evaluated in a dissolution vessel (USP dissolution tester) filled with 500 ml of simulated gastric fluid (pH 1.2) without pepsin and phosphate-buffered saline (PBS, pH 7.4). Paddle rotation speeds of 0 and 100 rpm were tested. Temperature was maintained at 37 °C. Fifty beads were placed in the

Table 1
The effect of gas-forming agents on bead size in wet and dry conditions

Gas-forming agent/alginate (w/w)		Wet AVE (mm) \pm S.D.	Dry AVE (mm) \pm S.D.
Control	0	2.24 \pm 0.01	1.10 \pm 0.04
CaCO ₃	0.25	2.23 \pm 0.08	1.20 \pm 0.02
	0.5	2.34 \pm 0.03	1.58 \pm 0.06
	0.75	2.42 \pm 0.01	1.87 \pm 0.05
	1	2.52 \pm 0.07	1.88 \pm 0.03
	0.25	2.39 \pm 0.05	1.29 \pm 0.09
NaHCO ₃	0.5	2.49 \pm 0.00	1.61 \pm 0.05
	0.75	2.91 \pm 0.02	2.45 \pm 0.04

Table 2
Porosity and mean pore diameter of floating beads

Gas-forming agent/alginate (w/w)		Porosity AVE (%) \pm S.D.	Median pore diameter AVE (μ m) \pm S.D.
Control		80.08 \pm 0.32	0.37 \pm 0.03
CaCO ₃	0.25	88.84 \pm 3.21	0.50 \pm 0.14
	0.5	89.10 \pm 0.99	1.83 \pm 0.38
	0.75	94.78 \pm 4.70	6.14 \pm 2.53
	0.25	91.48 \pm 3.09	1.28 \pm 0.83
NaHCO ₃	0.5	91.85 \pm 1.79	20.82 \pm 0.33
	0.75	95.14 \pm 0.89	39.72 \pm 3.27

media and the percentage of floating samples was measured by visual observation ($n = 3$).

2.4.2. *In vitro* riboflavin release studies

Release studies were performed in triplicate using the USP paddle method at 100 rpm and 37 °C in 500 ml of PBS media. Approximately fifty beads were used for each experiment. Samples were taken at appropriate time intervals and assayed spectrophotometrically at 444 nm. Fresh media was added to replace the sample taken.

3. Results

3.1. The effects of CO₂ gas-forming agents on bead size

A range of weight ratios of NaHCO₃ and CaCO₃ was used to determine the effects of the gas-forming process on the size of beads formed (Table 1). Table 1 shows that both gas-forming

agents significantly increased the size of the beads over the control (no gas-forming agent). This effect was especially remarkable in the case of NaHCO₃. Moreover, when NaHCO₃ was added to the alginate solution at a 1:1 ratio, spherical beads could not be formed because released CO₂ gas burst the bead before the wall was sufficiently hardened.

3.2. Porosity and pore size of floating beads

Porosity and volume average pore diameter was studied to determine the effects of gas-forming agents on pore structure of the floating beads. By increasing the ratio of incorporated gas forming agents from 0 to 0.75, the porosity and pore diameter of the beads were increased from 80.0% and 0.37 μ m to 94.8% and 6.14 μ m, respectively, with CaCO₃, and to 95.1% and 39.72 μ m with NaHCO₃ (Table 2). Although the porosity of the beads was similar, it was clearly demonstrated that NaHCO₃ produced larger pores than CaCO₃.

3.3. The effects on floating ability of gas-forming agents

The floating ability of prepared beads was evaluated in simulated gastric fluid and PBS buffer (Table 3). While gas-forming agent free beads sink uniformly in both media, beads containing gas-forming agents in proportions ranging from 0.5:1 to 1:1 ratios demonstrated excellent floating ability (100% floating). The wet beads (0.25 gas-forming agent/alginate, w/w) had better floating ability than dry beads. Floating ability is directly related to the gas content of the polymer matrix. Wet beads can contain a greater proportion of CO₂ gas than dry ones and are thus more buoyant. These results were not affected by paddle speed (fixed at 0 and 100 rpm). The floating abilities persisted until disintegration of the beads began (over 30 min). In addition, differences between samples were not significant at any stage during the experiment.

3.4. The effects on surface and cross-sectional morphology

Figs. 1 and 2 show the surface and cross-sectional SEM pictures of the beads prepared with CaCO₃ and NaHCO₃ components. The gas-forming agent free bead has a rough surface. While the NaHCO₃ treated bead did not show a significantly improved surface character, (Fig. 1f–h), increased ratios of incorporated CaCO₃ made the bead surface smoother (Fig. 1a–e). It is suggested that the presence of Ca²⁺ ions contributed to homogenous alginate bead formation. In some experiments CaCO₃ has been used as a gelling agent to aid the internal gelation of the alginate (Johnson et al., 1997; Poncelet et al., 1999). In acid conditions the salt dissociates to release divalent calcium cations that interact with the alginate. In spite of improved gellation, cracks were shown on surface of the 1:1 CaCO₃:alginate beads (Fig. 1e); and SEM photographs reveal the presence of riboflavin crystals on bead surface (Fig. 1a–h).

The cross-sectional morphologies of floating beads were also examined with SEM (Fig. 2). Many large closed pores are present in the alginate gel matrix. The number of observed pores appears to be directly related to the amount of incorporated gas-forming agent. Additionally, it

Table 3

Floating ability of beads in simulated gastric fluid (pH 1.2) and PBS buffer (pH 7.4): – – completely sink; – slightly float; +/- partially sink or float; ++ completely float; + slightly sink

Variables				Gas-forming agent/alginate (w/w)				
				0	0.25	0.5	0.75	1
Simulated gastric fluid (pH 1.2)	CaCO ₃	Wet	Stand	– –	++	++	++	++
			100 rpm	–	+	++	++	++
	Dry	Stand	Stand	–	–	++	++	++
			100 rpm	–	+/-	++	++	++
	NaHCO ₃	Wet	Stand	– –	++	++	++	++
			100 rpm	–	+	++	++	++
Dry	Stand	Stand	–	+	++	++	++	
		100 rpm	–	+	++	++	++	
PBS buffer (pH 7.4)	CaCO ₃	Wet	Stand	– –	++	++	++	++
			100 rpm	–	++	++	++	++
	Dry	Stand	Stand	– –	+/-	++	++	++
			100 rpm	– –	+/-	++	++	++
	NaHCO ₃	Wet	Stand	– –	++	++	++	++
			100 rpm	–	+	++	++	++
Dry	Stand	Stand	– –	+/-	++	++	++	
		100 rpm	– –	+/-	++	++	++	




Fig. 1. SEM photographs, surface morphologies. Bar, 50 μm : (a) Control; (b) 0.25 CaCO_3 /alginate (w/w); (c) 0.5 CaCO_3 /alginate; (d) 0.75 CaCO_3 /alginate; (e) 1 CaCO_3 /alginate; (f) 0.25 NaHCO_3 /alginate; (g) 0.5 NaHCO_3 /alginate; (h) 0.75 NaHCO_3 /alginate (—►: Riboflavin crystal, - -►: Crack).




Fig. 2. SEM photographs (cross-sectional morphologies): (a) 0.5 CaCO_3 /alginate (w/w); (b) 0.5 NaHCO_3 /alginate; (c) 1 CaCO_3 /alginate.

was established that NaHCO_3 produced much larger pores than CaCO_3 . This result is in accordance with the porosity and pore size data of Table 2.

3.5. Mechanical strength of gas-forming agent treated beads

Mechanical testing was performed in order to study the effect of gas forming agents on the gel strength of floating beads. Fig. 3 shows the tendency for gel strength to decrease with increasing gas forming agent content. A high proportion of gas-forming agent made the beads highly porous and fragile. As also shown in Fig. 3, it was established that CaCO_3 containing beads possessed a significantly stronger gel than those containing NaHCO_3 . This is due to the internal

ionotropic gelation effect of CaCO_3 on alginate. It has been shown that Ca divalent ions make stronger alginate gels than Na ions. Johnson et al. (1997) investigated the mean maximum breaking strengths of rafts formed using a range of alginates, carbonates and bicarbonates. In the case of a LFR5/60 alginate sample, the gel strength of NaHCO_3 -treated rafts was 44.6 mN, but the gel strength of CaCO_3 -treated rafts was 58.9 mN.

3.6. Release profiles of floating beads

The release rates of riboflavin from wet and dried alginate beads with different amounts of NaHCO_3 and CaCO_3 are shown in Fig. 4. Riboflavin was exhausted from dried beads more quickly than from wet beads. The freeze drying process tends to make samples more porous.

Freeze dried beads disintegrate more readily in the dissolution tester due to increased water uptake. In addition, dry beads are more fragile and susceptible to shear stress from rotating paddles. In the absence of gas-forming agent the release rate was very slow. The rate of drug release was found to increase with increasing weight ratios of NaHCO_3 . This is a direct result of the porous nature of the NaHCO_3 containing beads. The highly dense internal structure of the alginate beads prepared without gas forming agents was expected to retain the drug more effectively. Conversely, increasing the CaCO_3 weight ratio prolongs the release rate of riboflavin from the alginate matrix. The effect is observed in spite of increased bead porosity and pore size and may be due to the internal ionotropic gelation effect of CaCO_3 (Poncelet et al., 1999). CaCO_3 is present as an insoluble dispersion in neutral pH aqueous alginate solution; however, in acidic media, the CaCO_3 becomes water-soluble. The ionized Ca^{2+} ions then promote internal gelation by cross-linking with the alginate carboxyl group. More significant differences in release profile would be expected from in vivo experiments or more suit-

able in vitro tests. Standard dissolution methods based on USP or British Pharmacopoeia (BP) have been shown to be poor predictors of in vitro release for floating dosage forms due to reduced shear stress on the floating beads (Pillay and Fassihi, 1998).

4. Discussion

There were two principle objectives to this study. Firstly, the use of CaCO_3 and NaHCO_3 for the production of floating alginate beads was investigated using a simple dripping method. The data presented here has established that these gas-forming agents are highly effective for floating bead formation. The second objective was to assess the effects of formulation variables on bead characteristics and to compare CaCO_3 and NaHCO_3 as gas-forming agents. The study has clearly shown that the kind and amount of gas-forming agent has a profound effect on size, floating ability, pore structure, morphology, release rate and mechanical strength of floating beads. In general, CaCO_3 -formed smaller and




Fig. 3. The effect of gas-forming agents on mechanical strength of beads.







Fig. 4. The effect of gas forming agents on releasing rate: (a) wet, NaHCO₃; (b) dry, NaHCO₃; (c) wet, CaCO₃; (d) dry CaCO₃.

stronger floating beads than NaHCO₃. Consequently, beads formed with CaCO₃ significantly extended drug release. Overall, it was demonstrated that although CaCO₃ is a less effective gas-forming agent than NaHCO₃, it produced superior floating beads with enhanced control of

drug release rates. By delineation of the formulation variables, it is hoped that further research with a variety of gas-forming agents and new preparation methods for floating microspheres will lead to the development of more effective FDD Systems.



c)



d)

Fig. 4. (Continued)

Acknowledgements

This work was supported by a grant of the Korea Health 21 R&D Project, Ministry of Health & Welfare, Republic of Korea (HMP-00-PT-21700-0017).

References

Akiyama, Y., Nagahara, N., Nara, E., Kitano, M., Iwasa, S., Yamamoto, I., Azuma, J., Ogawa, Y., 1998. Evaluation of oral mucoadhesive microspheres in man on the basis of the pharmacokinetics of furosemide and riboflavin, compounds with limited gastrointestinal absorption sites. *J.*

- Pharm. Pharmacol. 50, 159–166.
- Badwan, A.A., Abumaloo, A., Sallam, E., Abukalaf, A., Jawan, O., 1985. A sustained release drug delivery system using calcium alginate beads. *Drug Dev. Ind. Pharm.* 11, 239–256.
- Baumgartner, S., Kristl, J., Vrecer, F., Vodopivec, P., Zorko, B., 2000. Optimisation of floating matrix tablets and evaluation of their gastric residence time. *Int. J. Pharm.* 195, 125–135.
- Bulgarelli, E., Forni, F., Bernabei, M.T., 2000. Effect of matrix composition and process conditions on casein-gelatin beads floating properties. *Int. J. Pharm.* 198, 157–165.
- Catherine, K.K., Peter, X.M., 2001. Ionically crosslinked alginate hydrogels as scaffolds for tissue engineering: Part 1. Structure, gelation rate and mechanical properties. *Biomaterials* 22, 511–521.
- Chen, J., Park, K., 2000. Synthesis of fast-swelling, superporous sucrose hydrogels. *Carbohydr. Polym.* 41, 259–268.
- Chickering, D.E. III, Jacob, J.S., Desai, T.A., Harrison, M., Harris, W.P., Morrell, C.N., Chaturvedi, P., Mathiowitz, E., 1997. Bioadhesive microspheres: III. An in vivo transit and bioavailability study of drug-loaded alginate and poly(fumaric-co-sebacic anhydride) microspheres. *J. Control. Rel.* 48, 35–46.
- Desai, S., Bolton, S., 1993. A floating controlled-release drug delivery system: In vitro-in vivo evaluation. *Pharm. Res.*, 10, 1321–1325.
- Deshpande, A.A., Shah, N.H., Rhodes, C.T., Malick, W., 1997. Development of a novel controlled-release system for gastric retention. *Pharm. Res.* 14, 815–819.
- El-kamel, A.H., Sokar, M.S., Al Gamal, S.S., Naggar, V.F., 2001. Preparation and evaluation of ketoprofen floating oral delivery system. *Int. J. Pharm.* 220, 13–21.
- Grant, G.T., Morris, E.R., Rees, D.A., Smith, P.J.C., Thom, D., 1973. Biological interactions between polysaccharides and divalent cations: the egg-box model. *FEBS Lett.* 2, 195–198.
- Gray, C.J., Dowsett, J., 1988. Retention of insulin in alginate gel beads. *Biotech. Bioeng.* 31, 607–612.
- Iannuccelli, V., Coppi, G., Bernabei, M.T., Cameroni, R., 1998. Air compartment multiple-unit system for prolonged gastric residence. Part 1. Formulation study. *Int. J. Pharm.* 174, 47–54.
- Ichikawa, M., Watanabe, S., Miyake, Y., 1991. A new multiple-unit oral floating drug delivery system. I: preparation and in vitro evaluation of floating and sustained-release characteristics. *J. Pharm. Sci.* 80, 1062–1066.
- Johnson, F.A., Craig, D.Q.M., Mercer, A.D., Chanhan, S., 1997. The effects of alginate molecular structure and formulation variables on the physical characteristics of alginate raft systems. *Int. J. Pharm.* 159, 35–42.
- Katayama, H., Nishimura, T., Ochi, S., Tsuruta, Y., Yamazaki, Y., Shibata, K., Yoshitomi, H., 1999. Sustained release liquid preparation using sodium alginate for eradication of *Helicobacter pylori*. *Biol. Pharm. Bull.* 22, 55–60.
- Kawashima, Y., Niwa, T., Takeuchi, H., Hino, T., Itoh, Y., 1992. Hollow microspheres for use as a floating controlled drug delivery system in the stomach. *J. Pharm. Sci.* 81, 135–140.
- Kedzierewicz, F., Thouvenot, P., Lemut, J., Etienne, A., Hoffman, M., Maincent, P., 1999. Evaluation of peroral silicone dosage forms in humans by gamma-scintigraphy. *J. Control. Rel.* 58, 195–205.
- Mandel, K.G., Daggy, B.P., Brodie, D.A., Jacoby, H.I., 2000. Alginate-raft formulations in the treatment of heartburn and acid reflux. *Aliment. Pharmacol. Ther.* 14, 669–690.
- Murata, Y., Sasaki, N., Miyamoto, E., Kawashima, S., 2000. Use of floating alginate gel beads for stomach-specific drug delivery. *Eur. J. Pharm. Biopharm.* 50, 221–226.
- Park, Y.J., Liang, J., Yang, Z., Yang, V.C., 2001. Controlled release of clot-dissolving tissue-type plasminogen activator from a poly(L-glutamic acid) semi-interpenetrating polymer network hydrogel. *J. Control. Rel.* 75, 37–44.
- Pillay, V., Fassihi, R., 1998. Evaluation and comparison of dissolution data derived from different modified release dosage forms; and alternative method. *J. Control. Rel.* 55, 45–55.
- Poncelet, D., Babak, V., Dulieu, C., Picot, A., 1999. A physico-chemical approach to production of alginate beads by emulsification-internal ionotropic gelation. *Colloids Surf. A* 155, 171–176.
- Rouge, N., Buri, P., Doelker, E., 1996. Drug absorption sites in the gastrointestinal tract and dosage forms for site-specific delivery. *Int. J. Pharm.* 136, 117–139.
- Rouge, N., Allemann, E., Gex-Fabry, M., Balant, L., Cole, E.T., Buri, P., Doelker, E., 1998. Comparative pharmacokinetic study of a floating multiple-unit capsule, a high density multiple-unit capsule and an immediate-release tablet containing 25 mg atenolol. *Pharm. Acta Helvetiae* 73, 81–87.
- Singh, B.M., Kim, K.H., 2000. Floating drug delivery systems: an approach to oral controlled drug delivery via gastric retention. *J. Control. Rel.* 63, 235–259.
- Smidsrod, O., Haug, A., 1965. The effect of divalent metals on the properties of alginate solutions. I. Calcium ions. *Acta Chem. Scand.* 19, 329–340.
- Sultana, K., Godward, G., Reynolds, N., Arumugaswamy, R., Peiris, P., Kailasapathy, K., 2000. Encapsulation of probiotic bacteria with alginate-starch and evaluation of survival in simulated gastrointestinal conditions and in yoghurt. *Int. J. Food Microbiol.* 62, 47–55.
- Thanoo, B.C., Sunny, M.C., Jayakrishnan, A., 1993. Oral sustained-release drug delivery systems using polycarbonate microspheres capable of floating on the gastric fluid. *J. Pharm. Pharmacol.* 45, 21–24.
- Timmermans, J., Moes, A.J., 1994. Factors controlling the buoyancy and gastric retention capabilities of floating matrix capsules: new data for reconsidering the controversy. *J. Pharm. Sci.* 83, 18–24.
- Whitehead, L., Collett, J.H., Fell, J.T., 2000. Amoxicillin release from a floating dosage form based on alginates. *Int. J. Pharm.* 210, 45–49.
- Zaniboni, H.C., Fell, J.T., Collett, J.H., 1995. Production and characterisation of enteric beads. *Int. J. Pharm.* 125, 151–155.